The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $173.49

Today's change+3.06 +1.80%
Updated November 26 11:58 AM EST. Delayed by at least 15 minutes.
 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $173.49

Today's change+3.06 +1.80%
Updated November 26 11:58 AM EST. Delayed by at least 15 minutes.

Jazz Pharmaceuticals PLC crosses above 20-day moving average

Jazz Pharmaceuticals PLC is up sharply today, rallying (U.S.)$3.06 or 1.80% to (U.S.)$173.49 and crossing above its 20-day moving average. Over the last five days, shares have gained 1.49% and are currently 3.62% off of the 52-week high. Shares have outperformed the S&P 500 by 37.91% during the last year.

Key company metrics

  • Open(U.S.) $171.46
  • Previous close(U.S.) $170.43
  • High(U.S.) $173.91
  • Low(U.S.) $170.62
  • Bid / Ask(U.S.) $173.48 / (U.S.) $173.57
  • YTD % change+37.08%
  • Volume244,879
  • Average volume (10-day)888,946
  • Average volume (1-month)833,383
  • Average volume (3-month)850,226
  • 52-week range(U.S.) $108.58 to (U.S.) $180.00
  • Beta0.64
  • Trailing P/E408.82×
  • P/E 1 year forward20.56×
  • Forward PEG0.84×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.42
Updated November 26 11:58 AM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2.87%

Based on its net profit margin of 2.87%, Jazz Pharmaceuticals PLC is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.21%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue307291247236
Total other revenue--------
Total revenue307291247236
Gross profit280261216210
Total cost of revenue27313126
Total operating expense249217314141
Selling / general / administrative9410110681
Research & development972014514
Depreciation / amortization31333121
Interest expense (income), net operating--------
Unusual expense (income)033--0
Other operating expenses, total--------
Operating income5874-6794
Interest income (expense), net non-operating-15-11-10-6
Gain (loss) on sale of assets--------
Other--------
Income before tax5063-7787
Income after tax2644-9455
Income tax, total24191732
Net income2644-9355
Total adjustments to net income--------
Net income before extra. items2644-9355
Minority interest001--
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items2644-9355
Inc. avail. to common incl. extra. items2644-9355
Diluted net income2644-9355
Dilution adjustment----0--
Diluted weighted average shares63625962
Diluted EPS excluding extraordinary itemsvalue per share0.410.70-1.580.90
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.261.13-1.380.95